Treatment

zenocutuzumab (MCLA-128) clinical trials

1 indexed studies · 0 currently recruiting

Active not recruitingPHASE2
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
This study is looking at a new drug called zenocutuzumab for people with certain solid cancers that have a specific genetic change (called an NRG1 fusion). It aims to see if the drug is safe, how well it's tolerated, and if it can help shrink the cancer.
For: Solid Tumours Harboring NRG1 Fusion · NSCLC Harboring NRG1 Fusion · Pancreatic Cancer Harboring NRG1 Fusion
United States · Austria · Belgium